Created at 6:48 p.m. Apr, 14, 2026
Author: bethani.demaria
Related Note: 1509297794322 1
Rationale for change

The 1st line treatment for NSCLC has been osimertinib since 2018. this info may be outdated. There are also no cards on Osimertinib. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-first-line-treatment-metastatic-nsclc-most-common-egfr-mutations#:~:text=On%20April%2018%2C%202018%2C%20the,by%20an%20FDA%2Dapproved%20test.

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Empty field
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::11_Cell_Cycle_Independent_Drug_Targets #AK_Step1_v12::#Textbooks::#Golan_Pharmacology::33_Principles_Of_Antimicrobial_and_Antineoplastic_Pharmacology #AK_Step1_v12::#Textbooks::#Cecil::057_Lung_Cancer #AK_Step1_v12::#OME_banner #AK_Step1_v12::#Textbooks::#Golan_Pharmacology::40_Pharmacology_Of_Cancer_Signal_Transduction #AK_Step1_v12::#AMBOSS #AK_Other::#AK_Original_Decks::Step_1::Lolnotacop::Drugs #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::03_Kinase_Inhibitors_&_Monoclonal_Antibodies::01_Kinase_Inhibitors #AK_Step1_v12::#AMBOSS::RTalqP #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::16_Erlotinib #AK_Step1_v12::#Textbooks::#Cecil::054_Cancer_Biology #AK_Step1_v12::#Low/HighYield::3-HighYield-temporary #AK_Other::Only_Step_1 #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::08_Principles_of_Oncology_and_Therapeutics::11_Cell_Cycle_Independent_Drug_Targets #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::19_Anticancer_small_molecule_inhibitors::*Erlotinib #AK_Step1_v12::#Bootcamp::Neurology::19_Adult_Primary_Brain_Tumors::02_Glioblastoma_Multiforme #AK_Step1_v12::#B&B::12_Hematology::04_Cancer_Drugs::06_Other_Cancer_Drugs